Survivorship – Ovarian Cancer (Includes Fallopian Tube and Peritoneal Primary)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

SURVEILLANCE

Annual physical exam with:
- Pelvic exam
- CA-125
- Other markers based on pathology¹

MONITORING FOR LATE EFFECTS

Consider the following:
- Colonoscopy
- Bone Health (see Gynecologic Cancer Survivorship: Bone Health algorithm)
- Sexual health

RISK REDUCTION/EARLY DETECTION

Patient education, counseling, and screening:
- Lifestyle risk assessment²
- Cancer screening³
- HPV vaccination as clinically indicated (see HPV Vaccination algorithm)
- Screening for Hepatitis B and C as clinically indicated (see Hepatitis Screening and Management – HBV and HCV algorithm)
- Consider cardiovascular risk reduction⁴
- Genetic screening⁵ (see Genetic Counseling algorithm)

PSYCHOSOCIAL FUNCTIONING

Assess for:
- Distress management (see Distress Screening and Psychosocial Management algorithm)
- Social support
- Financial stressors

CONCURRENT COMPONENTS OF VISIT

New primary or recurrent disease?

Yes

Return to primary treating physician

No

Continue survivorship monitoring

DISPOSITION

MONITORING FOR LATE EFFECTS

Ovarian cancer 5 years post-treatment and NED

SURVEILLANCE

NED = no evidence of disease

¹ Choriocarcinoma (ovarian) and Gestational trophoblastic disease – BHCG
² Mucinous type (ovarian) – CEA
³ Includes breast, cervical (if appropriate), colorectal, liver, lung, pancreatic, and skin cancer screening
⁴ Consider use of Vanderbilt’s ABCDE’s approach to cardiovascular health
⁵ Consider genetic counseling if there has been a significant family history change since the last genetic consult, or if the patient has not previously had BRCA1/BRCA2 genetic testing and ovarian cancer histology is high grade non-mucinous epithelial

Approved by the Executive Committee of the Medical Staff on 08/27/2019

Department of Clinical Effectiveness V8

Copyright 2019 The University of Texas MD Anderson Cancer Center
SUGGESTED READINGS


This survivorship algorithm is based on majority expert opinion of the Gynecologic Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Therese Bevers, MD (Cancer Prevention)
Diane C. Bodurka, MD (Education)
Robin Coyne, FNP, RN (Cancer Prevention)
Molly S. Daniels, MS, CGC (Clinical Cancer Genetics)
Terri Earles, WHNP-BC (Gyn Onc & Reproductive Med)
David M. Gershenson, MD (Gyn Onc & Reproductive Med)
Thoa Kazantsev, BSN, RN, OCN
Shiney Kurian, WHNP-BC (Gyn Onc & Reproductive Med)
Marita Lazzaro, RN, MS, ANP (Cancer Prevention)
Paula Lewis-Patterson, DNP, RN, NEA-BC (Cancer Survivorship)

*Clinical Effectiveness Development Team